| The macrophages in rheumatic diseases A Laria, A Lurati, M Marrazza, D Mazzocchi, KA Re, M Scarpellini Journal of inflammation research, 1-11, 2016 | 176 | 2016 |
| Efficacy of repeated intravenous infusions of an anti–tumor necrosis factor α monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis … V Gerloni, I Pontikaki, M Gattinara, F Desiati, E Lupi, A Lurati, A Salmaso, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2005 | 139 | 2005 |
| Evaluation of nailfold videocapillaroscopic abnormalities in patients with systemic lupus erythematosus F Ingegnoli, S Zeni, L Meani, A Soldi, A Lurati, F Fantini JCR: Journal of Clinical Rheumatology 11 (6), 295-298, 2005 | 91 | 2005 |
| Biomarkers, type II collagen, glucosamine and chondroitin sulfate in osteoarthritis follow-up: the “Magenta osteoarthritis study” M Scarpellini, A Lurati, G Vignati, MG Marrazza, F Telese, K Re, A Bellistri Journal of Orthopaedics and Traumatology 9, 81-87, 2008 | 82 | 2008 |
| Tumour necrosis factor alpha inhibitor therapy and rehabilitation for the treatment of ankylosing spondylitis: a systematic review E Lubrano, A Spadaro, G Amato, M Benucci, I Cavazzana, MS Chimenti, ... Seminars in arthritis and rheumatism 44 (5), 542-550, 2015 | 67 | 2015 |
| Accuracy of Wallace criteria for clinical remission in juvenile idiopathic arthritis: a cohort study of 761 consecutive cases A Lurati, A Salmaso, V Gerloni, M Gattinara, F Fantini The Journal of rheumatology 36 (7), 1532-1535, 2009 | 48 | 2009 |
| Macrophage activation syndrome (MAS) during anti-IL1 receptor therapy (anakinra) in a patient affected by systemic onset idiopathic juvenile arthritis (soJIA): A report and … A Lurati, B Teruzzi, A Salmaso, G Demarco, I Pontikati, M Gattinara, ... Pediatr Rheumatol Online J 3 (2), 79-85, 2005 | 44 | 2005 |
| Side effects of anti-TNFa therapy in juvenile idiopathic arthritis I Pontikaki, V Gerloni, M Gattinara, A Lurati, A Salmaso, G De Marco, ... Reumatismo 58 (1), 31-38, 2006 | 42 | 2006 |
| Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: a multicentre retrospective study P Sarzi-Puttini, D Marotto, R Caporali, CM Montecucco, EG Favalli, ... Journal of Autoimmunity 116, 102545, 2021 | 40 | 2021 |
| A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti–tumor necrosis factor α … A Lurati, I Pontikaki, B Teruzzi, F Desiati, V Gerloni, M Gattinara, R Cimaz, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2006 | 39 | 2006 |
| Effects of hyaluronic acid (HA) viscosupplementation on peripheral Th cells in knee and hip osteoarthritis A Lùrati, A Laria, D Mazzocchi, KA Re, M Marrazza, M Scarpellini Osteoarthritis and Cartilage 23 (1), 88-93, 2015 | 38 | 2015 |
| Interstitial lung disease in rheumatoid arthritis: a practical review A Laria, AM Lurati, G Zizzo, E Zaccara, D Mazzocchi, KA Re, M Marrazza, ... Frontiers in medicine 9, 837133, 2022 | 36 | 2022 |
| Successful Treatment of a Patient with Giant Cell Vasculitis (Horton Arteritis) with Tocilizumab a Humanized Anti‐Interleukin‐6 Receptor Antibody A Lurati, L Bertani, KA Re, M Marrazza, D Bompane, M Scarpellini Case reports in rheumatology 2012 (1), 639612, 2012 | 31 | 2012 |
| Different T cells’ distribution and activation degree of Th17 CD4+ cells in peripheral blood in patients with osteoarthritis, rheumatoid arthritis, and healthy donors … A Lurati, A Laria, A Gatti, B Brando, M Scarpellini Open Access Rheumatology: Research and Reviews, 63-68, 2015 | 23 | 2015 |
| Safety of etanercept in elderly subjects with rheumatoid arthritis A Lurati, M Marrazza, K Angela, M Scarpellini Biologics: Targets and Therapy, 1-4, 2010 | 20 | 2010 |
| NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab A Lurati, L Bertani, M Marrazza, KA Re, D Bompane, M Scarpellini Biologics: Targets and Therapy, 83-87, 2012 | 17 | 2012 |
| Skeletal mineralization in a prepubertal female population affected by juvenile idiopathic arthritis A Lurati, R Cimaz, M Gattinara, V Gerloni, B Teruzzi, A Salmaso, F Fantini Reumatismo 60 (3), 224-229, 2008 | 15 | 2008 |
| Macrophage activation syndrome (MAS) during anti‐IL1 therapy (anakinra) in a patient affected by systemic juvenile arthritis (soJIA): a report and review of the literature A Lurati Pediatr Rheumatol Online J 3, 79, 2005 | 14 | 2005 |
| Increased COVID-19 mortality in patients with rheumatic diseases: results from the CONTROL-19 study by the Italian Society for Rheumatology A Zanetti, G Carrara, G Landolfi, D Rozza, CB Chighizola, A Alunno, ... Clin Exp Rheumatol 40, 2038-43, 2022 | 13 | 2022 |
| Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy G De Marco, V Gerloni, I Pontikaki, A Lurati, B Teruzzi, A Salmaso, ... Reumatismo 59 (1), 50-56, 2007 | 12 | 2007 |
